BioRestorative Therapies, Inc. (NASDAQ:BRTX) Sees Large Increase in Short Interest

BioRestorative Therapies, Inc. (NASDAQ:BRTX) was the target of a large increase in short interest during the month of September. As of September 15th, there was short interest totalling 58,400 shares, an increase of 13.4% from the August 31st total of 51,500 shares. Based on an average trading volume of 56,300 shares, the short-interest ratio is currently 1.0 days. Approximately 1.2% of the company’s shares are short sold.

Institutional Investors Weigh In On BioRestorative Therapies

An institutional investor recently bought a new position in BioRestorative Therapies stock. StoneX Group Inc. bought a new stake in shares of BioRestorative Therapies, Inc. (NASDAQ:BRTX) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 34,850 shares of the company’s stock, valued at approximately $48,000. StoneX Group Inc. owned approximately 0.51% of BioRestorative Therapies at the end of the most recent quarter. 69.38% of the stock is currently owned by institutional investors.

BioRestorative Therapies Price Performance

Shares of BioRestorative Therapies stock opened at $1.74 on Tuesday. The firm has a market cap of $11.78 million, a PE ratio of -0.75 and a beta of 63.07. BioRestorative Therapies has a 12-month low of $1.03 and a 12-month high of $3.67. The company’s fifty day simple moving average is $1.60 and its two-hundred day simple moving average is $1.53.

BioRestorative Therapies (NASDAQ:BRTX) last announced its earnings results on Tuesday, August 13th. The company reported ($0.50) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.06. The firm had revenue of $0.09 million for the quarter, compared to analyst estimates of $0.03 million. BioRestorative Therapies had a negative net margin of 6,898.28% and a negative return on equity of 107.65%. During the same quarter in the previous year, the firm posted ($0.77) EPS. As a group, sell-side analysts expect that BioRestorative Therapies will post -1.83 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, Roth Mkm raised their price target on shares of BioRestorative Therapies from $15.00 to $18.00 and gave the stock a “buy” rating in a report on Wednesday, August 14th.

BioRestorative Therapies Company Profile

BioRestorative Therapies, Inc, a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders.